Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
Status:
Active, not recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the long-term side effects of ruxolitinib in treating patients
with myelofibrosis. Collecting data about the long-term safety and tolerability of
ruxolitinib may better help future patients with myelofibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Incyte Corporation National Cancer Institute (NCI)